MedTrace Logo

Using Three Different Doses of Hyperbaric Prilocaine 2% Local Anaesthetic ( 40,50 and 60mg ),Through Spinal Anaesthesia in Knee Arthroscopy Patients to Compare Time to Void

NCT06703580 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-02-10

No results posted yet for this study

Summary

The goal of this randomised trial is to use a short acting local anaesthetic drug (hyperbaric prilocaine 2%) which is beneficial in short operations which are performed as a day case surgery.

in this study the investigators will use 3 different doses of prilocaine 2% (40,50 or 60 mg ) intrathecal (in spinal anaesthesia) in participants undergoing arthroscopy on the knee.

the primary outcome is to compare time to micturate (go to the bathroom) between the three groups .

the secondary outcomes are:

* time to recovery of the motor and sensory block
* time to discharge from post anesthesia care unit
* any complications ; itching, lowered blood pressure, nausea and vomiting.

Conditions

  • Time to First Void After Spinal Anaesthesia

Interventions

DRUG

hyperbaric prilocaine 2% 50 mg

comparison of 3 different doses of prilocaine

DRUG

hyperbaric prilocaine 2% 60 mg

this study compare 3 different doses of prilocaine

DRUG

Hyperbaric prilocaine 2% 40 mg

this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • osama M Asad, professor of anaesthesia · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2025-12-27
Completion
2026-02-08

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06703580 on ClinicalTrials.gov